WINGER DENNIS L

Form 4

November 24, 2008

Biosystems Group

Common Stock 11/20/2008

11/21/2008

OMB APPROVAL UNITED STATES SECURITIES AND EXCHANGE COMMISSION OMB 3235-0287 Washington, D.C. 20549 Number: Check this box January 31, Expires: if no longer 2005 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF subject to Estimated average **SECURITIES** Section 16. burden hours per Form 4 or 0.5 response... Form 5 Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, obligations Section 17(a) of the Public Utility Holding Company Act of 1935 or Section may continue. 30(h) of the Investment Company Act of 1940 See Instruction 1(b). (Print or Type Responses) 1. Name and Address of Reporting Person * 5. Relationship of Reporting Person(s) to 2. Issuer Name and Ticker or Trading WINGER DENNIS L Issuer Symbol APPLIED BIOSYSTEMS INC. (Check all applicable) [ABI] (Last) (First) (Middle) 3. Date of Earliest Transaction Director 10% Owner X_ Officer (give title Other (specify (Month/Day/Year) below) below) APPLIED BIOSYSTEMS INC., 301 11/20/2008 Senior Vice President and CFO **MERRITT 7** (Street) 4. If Amendment, Date Original 6. Individual or Joint/Group Filing(Check Filed(Month/Day/Year) Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting NORWALK, CT 06851-1070 (City) (State) (Zip) Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of 2. Transaction Date 2A. Deemed 3. 4. Securities Acquired (A) or 5. Amount of 6. 7. Nature Security (Month/Day/Year) Execution Date, if TransactionDisposed of (D) Securities Ownership of Indirect (Instr. 3) Code (Instr. 3, 4 and 5) Beneficially Form: Beneficial (Month/Day/Year) (Instr. 8) Owned Direct (D) Ownership or Indirect Following (Instr. 4) Reported (I) (A) Transaction(s) (Instr. 4) or (Instr. 3 and 4) Price Code V Amount (D) Applied **Biosystems** Group 11/20/2008 Α 29,115 \$0 161,320.2555 D Common Stock **Applied**

F

D

12,560

148,760.2555

D

27.975

0

<u>(1)</u>

148,760.2555

D

Edgar Filing: WINGER DENNIS L - Form 4

Applied Biosystems Group Common Stock

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474

(9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	· · · · · · · · · · · · · · · · · · ·		ate	7. Title and Amou Underlying Secur (Instr. 3 and 4)
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title I
Applied Biosystems Group Employee Stock Options-Right to Buy	\$ 28.2343 (2)	11/21/2008		D	42,200 (2)	(3)	06/17/2009	Applied Biosystems Group Common Stock
Applied Biosystems Group Employee Stock Options-Right to Buy	\$ 28.2343	11/21/2008		D	42,200 (2)	(3)	06/17/2009	Applied Biosystems Group Common Stock
Applied Biosystems Group Employee Stock Options-Right to Buy	\$ 27.1875 (2)	11/21/2008		D	100,000	(3)	05/13/2009	Applied Biosystems Group Common Stock
Applied Biosystems Group	\$ 55.0625 (2)	11/21/2008		D	42,200 (2)	(3)	12/27/2009	Applied Biosystems Group

Edgar Filing: WINGER DENNIS L - Form 4

Employee Stock Options-Right to Buy							Common Stock
Applied Biosystems Group Employee Stock Options-Right to Buy	\$ 55.0625 (2)	11/21/2008	D	42,200 (2)	<u>(3)</u>	12/27/2009	Applied Biosystems Group Common Stock
Applied Biosystems Group Employee Stock Options-Right to Buy	\$ 100.4688 (2)	11/21/2008	D	100,000 (2)	<u>(3)</u>	03/17/2010	Applied Biosystems Group Common Stock
Applied Biosystems Group Employee Stock Options-Right to Buy	\$ 100.4688 (2)	11/21/2008	D	42,200 (2)	<u>(3)</u>	03/17/2010	Applied Biosystems Group Common Stock
Applied Biosystems Group Employee Stock Options-Right to Buy	\$ 61.4063 (2)	11/21/2008	D	42,200 (2)	<u>(3)</u>	06/15/2010	Applied Biosystems Group Common Stock
Applied Biosystems Group Employee Stock Options-Right to Buy	\$ 34.625 (2)	11/21/2008	D	56,000 (2)	<u>(3)</u>	01/30/2017	Applied Biosystems Group Common Stock

Reporting Owners

Reporting Owner Name / Address	Relationships						
	Director	10% Owner	Officer	Other			
WINGER DENNIS L			Senior Vice				
APPLIED BIOSYSTEMS INC.			President and				

Reporting Owners 3

301 MERRITT 7 NORWALK, CT 06851-1070 **CFO**

Signatures

/s/ Thomas P. Livingston, Attorney-In-Fact for Dennis L. Winger

11/24/2008

**Signature of Reporting Person

Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
 - On November 21, 2008, the issuer was acquired by Invitrogen Corporation (renamed Life Technologies Corporation) pursuant to an Agreement and Plan of Merger dated as of June 11, 2008 (as amended, the "merger agreement"). All shares of the issuer's Applied Biosystems Group common stock ("ABI stock") held by the reporting person at the time of the merger were exchanged for merger consideration pursuant to the merger agreement. The merger consideration consists of the right to receive, at the election of each
- (1) stockholder, either (1) \$17.10 in cash and 0.4543 of a share of Life Technologies common stock (plus an additional cash payment of \$1.05 per share paid as a merger consideration adjustment due to the trading price of ABI stock during a specified period of time prior to the merger), (2) \$38 in cash, or (3) 0.8261 shares of Life Technologies common stock (plus an additional cash payment of \$1.91 paid as a merger consideration adjustment due to the trading price of ABI stock during a specified period of time prior to the merger), in the case of (2) and (3) subject to proration in accordance with the merger agreement.
 - Pursuant to the merger agreement, upon completion of the merger each outstanding award of options to purchase shares of ABI stock was converted into an award to purchase shares of Life Technologies Corporation common stock. Each new stock option award became an award to purchase shares of Life Technologies common stock in an amount equal to the product of (x) 0.8698, multiplied by (y) the
- number of shares of ABI stock underlying the stock option award outstanding as of closing (rounded down to the nearest share). The exercise price per share of each converted option is equal to the exercise price per share of the option prior to conversion divided by the exchange ratio of 0.8698 (rounded up to the nearest cent).
- All of these ABI stock options were fully vested and free from all restrictions upon the completion of the merger described in Note 1

 (3) above. Some of the options held by the reporting person and reported in Table II had vested at various dates prior to the merger. Pursuant to the merger agreement, options that had not vested prior to the merger became fully vested upon completion of the merger.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Signatures 4